An observational study in Dementia, Alzheimer Disease and Dementia With Lewy Bodies, sponsored by University Health Network, Toronto. Recruiting at 4 sites in Canada. Open to participants aged 30 Years to 95 Years. Per ClinicalTrials.gov, last updated 2025-11-20.
Sponsored by University Health Network, Toronto · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Dementia by University Health Network, Toronto — 2 open to participants now, 4 under way, none of them phase 3. Dementia · University Health Network, Toronto.
Among the 13 studies in Dementia by University Health Network, Toronto, this one is the only one that started in 2023, is the only observational one, and was the 11th registered.
2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.
Browse Dementia studies →2 of the 13 studies in Dementia by University Health Network, Toronto are open now, in 1 country. Recruiting first, the newest first:
University Health Network, Toronto · Sites in Canada
Ages 65+
By country, each count listing its studies:
Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.
This study: 30 Years to 95 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 252 across 554 observational studies indexed under Dementia.
Median enrollment 60 across the 11 interventional studies, 500 across the 1 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Health Network, Toronto is the lead sponsor of 1,441 studies on the registry; 298 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.
2 of the studies in Dementia by University Health Network, Toronto that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06529744University Health Network, TorontoImproving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling | 2026-11 |
| NCT05867641University Health Network, TorontoVR&R: Providing Caregiver Respite by Managing BPSDs and Improving QoL in People with Dementia Using Immersive VR-Therapy | 2027-02-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Dementia by University Health Network, Toronto, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To develop a model to predict disease progression in a large cohort of patients across a variety of neurodegenerative diseases, including Mild Cognitive Impairment (MCI) and dementia due to any neurodegenerative disease, including Alzheimer's Disease (AD), Lewy Body Disease (LBD), Vascular Disease (VaD) and Frontotemporal lobar degeneration (FTLD).
The goal of this study is to create a model to predict disease progression in patients with mild cognitive impairments and forms of dementia. To accomplish this, the current study will evaluate different tests including: brain imaging (MRI), body fluid samples (blood and cerebrospinal fluid), skin biopsy, cognitive ability, and behavioural questionnaires. The study team hopes that this information can be used to guide diagnosis and better predict disease progression in patients with mild cognitive impairment and and early dementia.
Individuals who have been diagnosed with a mild cognitive impairment or early stage dementia that are between the ages of 30-95 can participate in the study as long as they have a study partner who can answer questionnaires at their 3 study visits and can complete a majority of assessments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Cognitive phenotype
Change in Toronto Cognitive Assessment (TorCA) scores out of 330, where lower scores indicate increasing cognitive impairments, and individual domains.
Time frame: Baseline, 6-month follow-up, 1-year follow-up
Assessment of DNA methylation (DNAm) from bloodwork
Biological age from DNA methylation (DNAm) collected via bloodwork compared to chronological age.
Time frame: Baseline
Neurodegenerative protein levels in biofluids and skin biopsy
Differences in protein levels between neurodegenerative diagnoses and predictive ability for change in TorCA
Time frame: Baseline, 6-month follow-up, 1-year follow-up
Structural and Functional Differences between neurodegenerative diseases via MRI of the brain
Brain volumes and white matter hyperintensity (WMH) load corresponding to Toronto Cognitive Assessment (TorCA) scores out of 330 where lower scores indicate increasing cognitive impairments.
Time frame: Baseline
Plan to share: No — Individual participant data will not be available to other researchers. Only anonymized responses to the cognitive assessment, clinical assessment, behavioural questionnaires and biofluid protein levels will be shared.
Started Nov 2023 (actual). Primary completion is estimated for Nov 2026, 36 months after the start.
Of 272 non-industry observational studies under Dementia, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 202. This study's planned 36 months is below that.
Counting every sponsor, half of 294 studies reached it within 65 months; a quarter within 29 and three quarters within 188.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Health Network, Toronto →